Cybin Inc. (CYBN)
Automate Your Wheel Strategy on CYBN
With Tiblio's Option Bot, you can configure your own wheel strategy including CYBN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CYBN
- Rev/Share 0.0
- Book/Share 12.3156
- PB 0.951
- Debt/Equity 0.0
- CurrentRatio 12.6027
- ROIC -0.43
- MktCap 246274733.5963
- FreeCF/Share -5.2284
- PFCF -2.4147
- PE -2.1989
- Debt/Assets 0.0
- DivYield 0
- ROE -0.3895
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CYBN | Guggenheim | -- | Buy | -- | $35 | March 13, 2025 |
News
FDA seen likely to grant emergency use authorizations for psychedelics, boosting sector stocks
Published: June 18, 2025 by: Proactive Investors
Sentiment: Positive
The Food and Drug Administration (FDA) may soon issue emergency use authorizations for psychedelic substances like psilocybin, proponents of psychedelic therapy believe, amid a shit in attitude towards psychedelic therapies under the Trump administration. Emergency use authorizations (EUAs) are considered a more likely near-term regulatory pathway for psychedelics such as psilocybin because, unlike full FDA approval, they require a lower standard of evidence, a report from health-oriented news website Stat published on Wednesday highlighted.
Read More
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder
Published: June 03, 2025 by: Business Wire
Sentiment: Neutral
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,318,477 in support of its CYB004 deuterated DMT program in development for the treatment of generalized anxiety disorder (“GAD”). The p.
Read More
Wall Street Analysts Think Cybin Inc. (CYBN) Could Surge 988.67%: Read This Before Placing a Bet
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 988.7% upside potential for Cybin Inc. (CYBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
Published: February 10, 2025 by: Business Wire
Sentiment: Neutral
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported unaudited financial results for its third quarter ended December 31, 2024, and recent business highlights. “As we advance our lead clinical programs, CYB003 and CYB004, our focus in 2025 remains on continued.
Read More
About Cybin Inc. (CYBN)
- IPO Date 2019-09-13
- Website https://www.cybin.com
- Industry Biotechnology
- CEO Douglas L. Drysdale
- Employees 50